NXTC NextCure Inc.

50.27
+0.35  (+1%)
Previous Close 49.92
Open 49.65
Price To Book 8.08
Market Cap 1,379,546,037
Shares 27,442,730
Volume 303,080
Short Ratio
Av. Daily Volume 561,760
Stock charts supplied by TradingView

NewsSee all news

  1. NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference

    BELTSVILLE, Md., Nov. 26, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  2. NextCure Announces Closing of Public Offering

    BELTSVILLE, Md., Nov. 19, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  3. NextCure Announces Pricing of Public Offering of Common Stock

    BELTSVILLE, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  4. NextCure Announces Proposed Public Offering of Common Stock

    BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  5. NextCure Reports Third Quarter 2019 Financial Results

    BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 part to be completed 4Q 2020.
NC318
Solid tumors

Latest News

  1. NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference

    BELTSVILLE, Md., Nov. 26, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  2. NextCure Announces Closing of Public Offering

    BELTSVILLE, Md., Nov. 19, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  3. NextCure Announces Pricing of Public Offering of Common Stock

    BELTSVILLE, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  4. NextCure Announces Proposed Public Offering of Common Stock

    BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  5. NextCure Reports Third Quarter 2019 Financial Results

    BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  6. NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial

    NC318 was well toleratedSingle agent activity observed in multiple tumor types, including a CR and a PR in NSCLCInitiated Phase 2 portion of the Phase 1/2 monotherapy trial and plans for a combo trial with standard of

  7. NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    BELTSVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing next-generation immunomedicines for cancer and other immune-related

  8. NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer

    BELTSVILLE, Md., Oct. 02, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  9. NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC

    BELTSVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer